Individualized Dose Study of ATG in Haploidentical Hematopoietic Stem Cell Transplantation
Phase 4
Completed
- Conditions
- Haploidentical Hematopoietic Stem Cell Transplantation
- Registration Number
- NCT05166967
- Lead Sponsor
- Chinese PLA General Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 204
Inclusion Criteria
Inclusion Criteria:<br><br> - <br><br> 1. All patients should have the indication of Haploidentical hematopoietic stem<br> cell transplant.<br><br> - <br><br> 2. All patients should sign an informed consent document indicating that they<br> understand the purpose of and procedures required for the study and be willing<br> to participate in the study.<br><br>Exclusion Criteria:<br><br>1.Patients with any conditions not suitable for the trial (investigators' decision).
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Cumulative incidences of CMV reactivation
- Secondary Outcome Measures
Name Time Method Incidence of CMV disease;Cumulative incidences of aGVHD;Cumulative incidences of cGVHD;Neutrophil engraftment;Platelet engraftment;Overall survival (OS);Disease-free survival (DFS);GRFS (GVHD free, relapse free survival);Nonrelapse mortality (NRM);Infection rate;Cumulative incidences of EBV reactivation;Cumulative incidences of PTLD(posttransplant lymphoproliferative disorders)